Continuing Medical Education Program – Purchase Activities

Continuing Medical Education Program – Purchase Activities

The purpose of The Medical Letter Continuing Medical Education Program is to provide a means for healthcare professionals (including physicians, physician assistants, nurse practitioners, and pharmacists) to keep up to date with new drugs and changes in therapeutics. The objectives of the program are to educate the participants, impact clinical practice, and improve patient outcomes. The Medical Letter CME Program is funded by fees paid by the activity participants. The Medical Letter is free of commercial influence and financial sponsorship.

   The Medical Letter Individual Activities — Online Only
I would like to order the following Per Issue Activities eligible for 2 credits each: $15 per activity
3 or more: $10/activity
1678 (2 credits)  Expires 05/30/2024
Drugs for Migraine
1679 (2 credits)  Expires 06/13/2024
Fezolinetant (Veozah) for Menopausal Vasomotor Symptoms
Brexpiprazole (Rexulti) for Agitation in Alzheimer's Dementia
Expanded Heart Failure Indication for Dapagliflozin (Farxiga)
Alternatives to Mifepristone for Medication Abortion
OTC Ivermectin for Head Lice
1680 (2 credits)
Drugs for Inflammatory Bowel Disease
1681 (2 credits)
Tofersen (Qalsody) for ALS
Sotagliflozin (Inpefa) for Heart Failure
Zavegepant (Zavzpret) for Acute Treatment of Migraine
Inspire for Obstructive Sleep Apnea
1682 (2 credits)
Drugs for Anxiety Disorders
1683 (2 credits)
Lecanemab (Leqembi) Granted Full Approval for Early Alzheimer's Disease
Bexagliflozin (Brenzavvy) - A Fifth SGLT2 Inhibitor for Type 2 Diabetes
Once-Weekly or Once-Monthly SC Buprenorphine (Brixadi) for Opioid Use Disorder
Linaclotide (Linzess) for Functional Constipation
1684 (2 credits) 
Drugs for Opioid Use Disorder
1685 (2 credits)
Nirsevimab (Beyfortus) for Prevention of Severe RSV Disease in Young Children
Suflave - A Low-Volume Colonoscopy Preparation
Opill - An OTC Oral Contraceptive
1686 (2 credits)
Two Vaccines (Arexvy and Abrysvo) for Prevention of RSV Disease
Lodoco: Low-Dose Colchicine for Cardiovascular Event Prevention
Valoctocogene Roxaparvovec (Roctavian) - A Gene Therapy for Severe Hemophilia
Delandistrogene Moxeparvovec (Elevidys) for Duchenne Muscular Dystrophy
1687 (2 credits)
Influenza Vaccine for 2023-2024
Nalmefene Nasal Spray (Opvee) for Reversal of Opioid Overdose
1688 (2 credits)
Drugs for Gout
AD-Detect - A Blood Test for Alzheimer's Disease
1689 (2 credits)
Antiviral Drugs for Influenza for 2023-2024
New Novavax Vaccine Formulation for 2023-2024
Empagliflozin (Jardiance) for Chronic Kidney Disease
1690 (2 credits)
Ritlecitinib (Litfulo) for Severe Alopecia Areata
Etrasimod (Velsipity) for Ulcerative Colitis
Sulbactam/Durlobactam (Xacduro) for Acinetobacter Pneumonia
Shockwave Therapy for Erectile Dysfunction
1691 (2 credits)
Drugs for Depression
1692 (2 credits)
Zuranolone (Zurzuvae) - An Oral Drug for Postpartum Depression
Vonoprazan (Voquezna) for Erosive Esophagitis
Tirzepatide (Zepbound) for Chronic Weight Management
Three New Injectable Antipsychotic Drugs
1693 (2 credits)
Treatment of Atrial Fibrillation
1694 (2 credits)
Casgevy and Lyfgenia: Two Gene Therapies for Sickle Cell Disease
Bimekizumab (Bimzelx) for Psoriasis
Perfluorohexyloctane Ophthalmic Solution (Miebo) for Dry Eye Disease
Avacincaptad Pegol (Izervay) for Geographic Atrophy in Age-Related Macular Degeneration
1695 (2 credits)
Drugs for Acne
Drugs for Rosacea
IV Ferric Carboxymaltose (Injectafer) for Iron Deficiency in Heart Failure
1696 (2 credits)
Daprodustat (Jesduvroq) for Anemia of Chronic Kidney Disease
Cantharidin Topical Solution (Ycanth) for Molluscum Contagiosum
Rozanolixizumab (Rystiggo) for Myasthenia Gravis
Balfaxar: Another Four-Factor PCC for Warfarin Reversal
1697 (2 credits)
Drugs for Menopausal Symptoms
Tenapanor (Xphozah) for Hyperphosphatemia in Chronic Kidney Disease
Severe Hypocalcemia with Denosumab (Prolia) in Chronic Kidney Disease
1698 (2 credits)
Airsupra: An Inhaled Albuterol/Budesonide Combination for Asthma
Penbraya: A Pentavalent Meningococcal Vaccine
Mirikizumab (Omvoh) for Ulcerative Colitis
A New OTC Naloxone Nasal Spray (RiVive)
1699 (2 credits)
Drugs for Bipolar Disorder
Omalizumab (Xolair) for Food Allergy
1700 (2 credits)
Roflumilast Foam (Zoryve) for Seborrheic Dermatitis
Cabtreo: A Three-Drug Gel for Acne
Zilucoplan (Zilbrysq) for Myasthenia Gravis
Donislecel (Lantidra) for Type 1 Diabetes
1701 (2 credits)
Resmetirom (Rezdiffra) for Metabolic Dysfunction-Associated Steatohepatitis
A New Indication for Semaglutide (Wegovy)
Intravenous Acetaminophen/Ibuprofen (Combogesic IV)
iDose TR - A Travoprost Implant for Glaucoma
Antibiotic Prophylaxis for Dental Procedures
1702 (2 credits)
Sotatercept (Winrevair) for Pulmonary Arterial Hypertension
A New Indication for Bempedoic Acid (Nexletol)
Sarilumab (Kevzara) for Polymyalgia Rheumatica
In Brief: Casgevy for Beta Thalassemia
COVID-19 Update: An EUA for Pemivibart (Pemgarda) for Pre-Exposure Prophylaxis
1703 (2 credits)
Drugs for Hypertension


ACCME The Medical Letter is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

The Medical Letter Inc. designates this enduring material for a maximum of 2 AMA PRA Category 1 Credit(s)TM.

Physicians should claim only the credit commensurate with the extent of their participation in the activity.

ABIM MOC Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 2 MOC points in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit. Your participation information will be shared with ABIM through PARS.

ABS CC Successful completion of this CME activity enables the learner to earn credit toward the CME requirements of the American Board of Surgery’s Continuous Certification program. It is the CME activity provider’s responsibility to submit learner completion information to ACCME for the purpose of granting ABS credit.

AAFP The AAFP has reviewed The Medical Letter Continuing Medical Education Program, and deemed it acceptable for AAFP credit. Term of approval is from 01/01/2024 to 12/31/2024. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

AAPA This activity has been reviewed by the AAPA Review Panel and is compliant with AAPA CME Criteria. PAs should only claim credit commensurate with the extent of their participation.

Accreditation Council on Pharmacy Education
The Medical Letter is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education. Each exam is acceptable for 2.0 hours of knowledge-based continuing education credit (0.2 CEU).